Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPD

Dirkje S Postma; Nicolas Roche; Gene Colice; Elliot Israel; Richard J Martin; Willem Mc van Aalderen; Jonathan Grigg; Anne Burden; Elizabeth V Hillyer; Julie von Ziegenweidt; Gokul Gopalan; David Price

doi:10.2147/COPD.S68289

Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPD

Dirkje S Postma, Nicolas Roche, Gene Colice, Elliot Israel, Richard J Martin, Willem Mc van Aalderen, Jonathan Grigg, Anne Burden, Elizabeth V Hillyer, Julie von Ziegenweidt, Gokul Gopalan, David Price

Research output: Contribution to journal › Article › peer-review

25 Citations (Scopus)

6 Downloads (Pure)

Abstract

PURPOSE: Small airway changes and dysfunction contribute importantly to airway obstruction in chronic obstructive pulmonary disease (COPD), which is currently treated with inhaled corticosteroids (ICS) and long-acting bronchodilators at Global initiative for Obstructive Lung Disease (GOLD) grades 2-4. This retrospective matched cohort analysis compared effectiveness of a representative small-particle ICS (extrafine beclomethasone) and larger-particle ICS (fluticasone) in primary care patients with COPD.

PATIENTS AND METHODS: Smokers and ex-smokers with COPD ≥40 years old initiating or stepping-up their dose of extrafine beclomethasone or fluticasone were matched 1:1 for demographic characteristics, index prescription year, concomitant therapies, and disease severity during 1 baseline year. During 2 subsequent years, we evaluated treatment change and COPD exacerbations, defined as emergency care/hospitalization for COPD, acute oral corticosteroids, or antibiotics for lower respiratory tract infection.

RESULTS: Mean patient age was 67 years, 57%-60% being male. For both initiation (n=334:334) and step-up (n=189:189) patients, exacerbation rates were comparable between extrafine beclomethasone and fluticasone cohorts during the 2 year outcome period. Odds of treatment stability (no exacerbation or treatment change) were significantly greater for patients initiating extrafine beclomethasone compared with fluticasone (adjusted odds ratio 2.50; 95% confidence interval, 1.32-4.73). Median ICS dose exposure during 2 outcome years was significantly lower (P<0.001) for extrafine beclomethasone than fluticasone cohorts (315 μg/day versus 436 μg/day for initiation, 438 μg/day versus 534 μg/day for step-up patients).

CONCLUSION: We observed that small-particle ICS at significantly lower doses had comparable effects on exacerbation rates as larger-particle ICS at higher doses, whereas initiation of small-particle ICS was associated with better odds of treatment stability during 2-years' follow-up.

Original language	English
Pages (from-to)	1163-1186
Number of pages	24
Journal	International journal of chronic obstructive pulmonary disease
Volume	9
DOIs	https://doi.org/10.2147/COPD.S68289
Publication status	Published - 17 Oct 2014

Bibliographical note

We thank Professor Neil Barnes for his contributions in the early stages of the analyses, and we gratefully acknowledge Victoria Thomas for her assistance with the statistical analyses and production of figures.

Keywords

COPD exacerbation
extrafine particle
matched cohort analysis
real life
small airways

Access to Document

10.2147/COPD.S68289

Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPD
This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php
Final published version, 4.17 MB

Cite this

Postma, D. S., Roche, N., Colice, G., Israel, E., Martin, R. J., van Aalderen, W. M., Grigg, J., Burden, A., Hillyer, E. V., von Ziegenweidt, J., Gopalan, G., & Price, D. (2014). Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPD. International journal of chronic obstructive pulmonary disease , 9, 1163-1186. https://doi.org/10.2147/COPD.S68289

Postma, DS, Roche, N, Colice, G, Israel, E, Martin, RJ, van Aalderen, WM, Grigg, J, Burden, A, Hillyer, EV, von Ziegenweidt, J, Gopalan, G & Price, D 2014, 'Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPD', International journal of chronic obstructive pulmonary disease , vol. 9, pp. 1163-1186. https://doi.org/10.2147/COPD.S68289

@article{5fd7cbb01181463ca2f5de571a8252ba,

title = "Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPD",

abstract = "PURPOSE: Small airway changes and dysfunction contribute importantly to airway obstruction in chronic obstructive pulmonary disease (COPD), which is currently treated with inhaled corticosteroids (ICS) and long-acting bronchodilators at Global initiative for Obstructive Lung Disease (GOLD) grades 2-4. This retrospective matched cohort analysis compared effectiveness of a representative small-particle ICS (extrafine beclomethasone) and larger-particle ICS (fluticasone) in primary care patients with COPD.PATIENTS AND METHODS: Smokers and ex-smokers with COPD ≥40 years old initiating or stepping-up their dose of extrafine beclomethasone or fluticasone were matched 1:1 for demographic characteristics, index prescription year, concomitant therapies, and disease severity during 1 baseline year. During 2 subsequent years, we evaluated treatment change and COPD exacerbations, defined as emergency care/hospitalization for COPD, acute oral corticosteroids, or antibiotics for lower respiratory tract infection.RESULTS: Mean patient age was 67 years, 57%-60% being male. For both initiation (n=334:334) and step-up (n=189:189) patients, exacerbation rates were comparable between extrafine beclomethasone and fluticasone cohorts during the 2 year outcome period. Odds of treatment stability (no exacerbation or treatment change) were significantly greater for patients initiating extrafine beclomethasone compared with fluticasone (adjusted odds ratio 2.50; 95% confidence interval, 1.32-4.73). Median ICS dose exposure during 2 outcome years was significantly lower (P<0.001) for extrafine beclomethasone than fluticasone cohorts (315 μg/day versus 436 μg/day for initiation, 438 μg/day versus 534 μg/day for step-up patients).CONCLUSION: We observed that small-particle ICS at significantly lower doses had comparable effects on exacerbation rates as larger-particle ICS at higher doses, whereas initiation of small-particle ICS was associated with better odds of treatment stability during 2-years' follow-up.",

keywords = "COPD exacerbation, extrafine particle, matched cohort analysis, real life, small airways",

author = "Postma, {Dirkje S} and Nicolas Roche and Gene Colice and Elliot Israel and Martin, {Richard J} and {van Aalderen}, {Willem Mc} and Jonathan Grigg and Anne Burden and Hillyer, {Elizabeth V} and {von Ziegenweidt}, Julie and Gokul Gopalan and David Price",

note = "We thank Professor Neil Barnes for his contributions in the early stages of the analyses, and we gratefully acknowledge Victoria Thomas for her assistance with the statistical analyses and production of figures.",

year = "2014",

month = oct,

day = "17",

doi = "10.2147/COPD.S68289",

language = "English",

volume = "9",

pages = "1163--1186",

journal = "International journal of chronic obstructive pulmonary disease ",

issn = "1176-9106",

publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPD

AU - Postma, Dirkje S

AU - Roche, Nicolas

AU - Colice, Gene

AU - Israel, Elliot

AU - Martin, Richard J

AU - van Aalderen, Willem Mc

AU - Grigg, Jonathan

AU - Burden, Anne

AU - Hillyer, Elizabeth V

AU - von Ziegenweidt, Julie

AU - Gopalan, Gokul

AU - Price, David

N1 - We thank Professor Neil Barnes for his contributions in the early stages of the analyses, and we gratefully acknowledge Victoria Thomas for her assistance with the statistical analyses and production of figures.

PY - 2014/10/17

Y1 - 2014/10/17

N2 - PURPOSE: Small airway changes and dysfunction contribute importantly to airway obstruction in chronic obstructive pulmonary disease (COPD), which is currently treated with inhaled corticosteroids (ICS) and long-acting bronchodilators at Global initiative for Obstructive Lung Disease (GOLD) grades 2-4. This retrospective matched cohort analysis compared effectiveness of a representative small-particle ICS (extrafine beclomethasone) and larger-particle ICS (fluticasone) in primary care patients with COPD.PATIENTS AND METHODS: Smokers and ex-smokers with COPD ≥40 years old initiating or stepping-up their dose of extrafine beclomethasone or fluticasone were matched 1:1 for demographic characteristics, index prescription year, concomitant therapies, and disease severity during 1 baseline year. During 2 subsequent years, we evaluated treatment change and COPD exacerbations, defined as emergency care/hospitalization for COPD, acute oral corticosteroids, or antibiotics for lower respiratory tract infection.RESULTS: Mean patient age was 67 years, 57%-60% being male. For both initiation (n=334:334) and step-up (n=189:189) patients, exacerbation rates were comparable between extrafine beclomethasone and fluticasone cohorts during the 2 year outcome period. Odds of treatment stability (no exacerbation or treatment change) were significantly greater for patients initiating extrafine beclomethasone compared with fluticasone (adjusted odds ratio 2.50; 95% confidence interval, 1.32-4.73). Median ICS dose exposure during 2 outcome years was significantly lower (P<0.001) for extrafine beclomethasone than fluticasone cohorts (315 μg/day versus 436 μg/day for initiation, 438 μg/day versus 534 μg/day for step-up patients).CONCLUSION: We observed that small-particle ICS at significantly lower doses had comparable effects on exacerbation rates as larger-particle ICS at higher doses, whereas initiation of small-particle ICS was associated with better odds of treatment stability during 2-years' follow-up.

AB - PURPOSE: Small airway changes and dysfunction contribute importantly to airway obstruction in chronic obstructive pulmonary disease (COPD), which is currently treated with inhaled corticosteroids (ICS) and long-acting bronchodilators at Global initiative for Obstructive Lung Disease (GOLD) grades 2-4. This retrospective matched cohort analysis compared effectiveness of a representative small-particle ICS (extrafine beclomethasone) and larger-particle ICS (fluticasone) in primary care patients with COPD.PATIENTS AND METHODS: Smokers and ex-smokers with COPD ≥40 years old initiating or stepping-up their dose of extrafine beclomethasone or fluticasone were matched 1:1 for demographic characteristics, index prescription year, concomitant therapies, and disease severity during 1 baseline year. During 2 subsequent years, we evaluated treatment change and COPD exacerbations, defined as emergency care/hospitalization for COPD, acute oral corticosteroids, or antibiotics for lower respiratory tract infection.RESULTS: Mean patient age was 67 years, 57%-60% being male. For both initiation (n=334:334) and step-up (n=189:189) patients, exacerbation rates were comparable between extrafine beclomethasone and fluticasone cohorts during the 2 year outcome period. Odds of treatment stability (no exacerbation or treatment change) were significantly greater for patients initiating extrafine beclomethasone compared with fluticasone (adjusted odds ratio 2.50; 95% confidence interval, 1.32-4.73). Median ICS dose exposure during 2 outcome years was significantly lower (P<0.001) for extrafine beclomethasone than fluticasone cohorts (315 μg/day versus 436 μg/day for initiation, 438 μg/day versus 534 μg/day for step-up patients).CONCLUSION: We observed that small-particle ICS at significantly lower doses had comparable effects on exacerbation rates as larger-particle ICS at higher doses, whereas initiation of small-particle ICS was associated with better odds of treatment stability during 2-years' follow-up.

KW - COPD exacerbation

KW - extrafine particle

KW - matched cohort analysis

KW - real life

KW - small airways

U2 - 10.2147/COPD.S68289

DO - 10.2147/COPD.S68289

M3 - Article

C2 - 25378918

SN - 1176-9106

VL - 9

SP - 1163

EP - 1186

JO - International journal of chronic obstructive pulmonary disease

JF - International journal of chronic obstructive pulmonary disease

ER -

Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPD

Abstract

Bibliographical note

Keywords

Access to Document

Fingerprint

Cite this